| Autor: |
Gurban, Petruta, Mambet, Cristina, Botezatu, Anca, Necula, Laura G., Matei, Lilia, Neagu, Ana Iulia, Pitica, Ioana Madalina, Dragu, Laura Denisa, Nastasie Schulman, Alina, Ataman, Marius, Nedeianu, Saviana, Chivu‐Economescu, Mihaela, Bleotu, Coralia, Anton, Gabriela, Diaconu, Carmen Cristina |
| Předmět: |
|
| Zdroj: |
Journal of Cellular & Molecular Medicine; Aug2024, Vol. 28 Issue 16, p1-7, 7p |
| Abstrakt: |
BCR::ABL1‐negative myeloproliferative neoplasms (MPNs) are clonal haematopoietic stem cell disorders characterized by specific driver mutations and an increased risk of both macrothrombosis and microthrombosis. Serotonin receptor type 1B (HTR1B) was found to be expressed by various solid tumours, and also primary bone marrow mononuclear cells from myelodysplastic neoplasm and acute myeloid leukaemia patients, representing a potential therapeutic target. In this study we assessed for the first time the expression levels of HTR1B mRNA in the peripheral blood mononuclear cells (PBMC) of 85 newly diagnosed MPN patients, consisting of 28 polycythemia vera, 25 essential thrombocythemia and 32 primary myelofibrosis cases. Levels of HTR1B expression between MPN subtypes and control group were not significantly different. However, at clinical data examination, it was observed that MPN patients with a recent history of major thrombosis and/or signs of impaired microcirculation exhibited significantly higher HTR1B expression levels compared to non‐thrombotic MPNs and control group. Moreover, thrombotic MPN patients had significantly higher HTR1B expression than patients with recent thrombosis and absence of MPN diagnostic criteria. These findings suggest that increased levels of HTR1B expression in PBMC might be associated with thrombosis in MPN patients, but larger studies are needed for confirmation, including testing of the receptor protein expression level. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text